/JNJ

JNJ Stock - Johnson & Johnson

Q: What is the analyst price target for JNJ?

Analyst price target information is not currently available for JNJ.

Q: What is JNJ's market cap?

Market capitalization information is not currently available for JNJ.

Healthcare|Drug Manufacturers - General|NYSE

$207.44-0.02%

$0.05 (-0.02%) • Jan 8

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+2.1%upside

Target: $211.80

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for JNJ

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.33

52W High$215.19

52W Low$140.68

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$88.82B	$85.16B	$79.99B	$78.74B	$82.58B
Gross Profit	$61.35B	$58.61B	$55.39B	$55.34B	$54.16B
Gross Margin	69.1%	68.8%	69.3%	70.3%	65.6%
Operating Income	$22.15B	$23.41B	$21.01B	$20.94B	$19.73B
Net Income	$14.07B	$35.15B	$17.94B	$20.88B	$14.71B
Net Margin	15.8%	41.3%	22.4%	26.5%	17.8%
EPS	$5.84	$13.88	$6.83	$7.93	$5.59

Company Overview

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Visit Website

Earnings History & Surprises

JNJ

Beat Rate

100%

Last 18 quarters

Avg Surprise

+4.6%

EPS vs Estimate

Beats / Misses

18/0

Last 12 quarters

Latest EPS

$2.80

Q4 2025

EPS Surprise History

Q1 24

+0.9%

$2.29vs$2.27

Q2 24

+2.7%

$2.71vs$2.64

Q3 24

+4.1%

$2.82vs$2.71

Q4 24

+9.5%

$2.42vs$2.21

Q1 25

+2.5%

$2.04vs$1.99

Q2 25

+7.4%

$2.77vs$2.58

Q3 25

+3.4%

$2.77vs$2.68

Q4 25

+1.4%

$2.80vs$2.76

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	Apr 13, 2026	—	—	—	—
Q1 2026	Jan 21, 2026	$2.53	—	—	—
Q4 2025	Oct 14, 2025	$2.76	$2.80	+1.4%	✓ BEAT
Q3 2025	Jul 16, 2025	$2.68	$2.77	+3.4%	✓ BEAT
Q2 2025	Apr 15, 2025	$2.58	$2.77	+7.4%	✓ BEAT
Q1 2025	Jan 22, 2025	$1.99	$2.04	+2.5%	✓ BEAT
Q4 2024	Oct 15, 2024	$2.21	$2.42	+9.5%	✓ BEAT
Q3 2024	Jul 17, 2024	$2.71	$2.82	+4.1%	✓ BEAT
Q2 2024	Apr 16, 2024	$2.64	$2.71	+2.7%	✓ BEAT
Q1 2024	Jan 23, 2024	$2.27	$2.29	+0.9%	✓ BEAT
Q4 2023	Oct 17, 2023	$2.52	$2.66	+5.6%	✓ BEAT
Q3 2023	Jul 20, 2023	$2.61	$2.80	+7.3%	✓ BEAT
Q2 2023	Apr 18, 2023	$2.51	$2.68	+6.8%	✓ BEAT
Q1 2023	Jan 24, 2023	$2.22	$2.35	+5.9%	✓ BEAT
Q4 2022	Oct 18, 2022	$2.49	$2.55	+2.4%	✓ BEAT
Q3 2022	Jul 19, 2022	$2.57	$2.59	+0.8%	✓ BEAT
Q2 2022	Apr 19, 2022	$2.60	$2.67	+2.7%	✓ BEAT
Q1 2022	Jan 25, 2022	$2.12	$2.13	+0.5%	✓ BEAT
Q4 2021	Oct 19, 2021	$2.37	$2.60	+9.7%	✓ BEAT
Q3 2021	Jul 21, 2021	$2.27	$2.48	+9.3%	✓ BEAT

Frequently Asked Questions about JNJ

What is JNJ's current stock price?

Johnson & Johnson (JNJ) is currently trading at $207.44 per share. The stock has moved -0.02% today.

What is the analyst price target for JNJ?

The average analyst price target for JNJ is $211.88, based on 1 analyst.

What sector is Johnson & Johnson in?

Johnson & Johnson operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the NYSE exchange.

What is JNJ's market cap?

Johnson & Johnson has a market capitalization of $499.78 billion, making it a mega-cap company.

Does JNJ pay dividends?

No, Johnson & Johnson does not currently pay a dividend to shareholders.